drugset / Trial / NCT06324396

IMProving DRug Dosing and Outcomes for Single VEntricle Patients With Fontan Associated Liver Disease

NCT06324396

NaSingle-groupOpen-labelTreatment

Summary

This is a single center, open-label, prospective, investigation to quantify the effects liver congestion and fibrosis has on hepatic drug metabolism and transport in children, adolescents, and young adults with Fontan circulation.

Timeline

Start
2024-03-01
Primary completion
2026-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Pravastatin Small molecule 20 mg Oral
Subject Pravastatin Small molecule 40 mg Oral
Subject Sildenafil Unknown 10 mg Oral
Subject Sildenafil Unknown 20 mg Oral